Boston Scientific (BSX) Stock: What Wall Street Expects from Earnings Wednesday

TLDR

• Boston Scientific reports Q2 earnings on July 29, with analyst focus on its heart device portfolio.
• The company launched a restructuring plan approved July 21, expected to cost $700M–$800M before taxes.
• The plan involves supply chain changes, factory shifts, and job cuts, running through end of 2029.
• Annual savings of ~$500M are expected once fully implemented, with much reinvested into growth.
• Wall Street expects revenue to grow 5.9% year on year this quarter, down from 22.8% growth a year ago.

Boston Scientific reports Q2 earnings on Wednesday, July 29. The current stock price sits at $45.55, against an average analyst price target of $72.25.

Boston Scientific Corporation, BSX

Wall Street is expecting revenue growth of 5.9% year on year this quarter. That’s a sharp slowdown from the 22.8% growth BSX posted in the same quarter last year.

Last quarter, Boston Scientific reported revenues of $5.20 billion, up 11.6% year on year. That beat analyst revenue expectations, though revenue guidance for the following quarter came in below estimates.

… Continue reading the full article at the original source below.